Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1

Fig. 2

Kaplan-Meier survival patients with hilar cholangiocarcinoma based on ADAM-28, ADAM-10, and ADAM-17 expression. a, b, c Cancer overexpressing ADAM-28 (A), ADAM-10 (B), and ADAM-17 (C) showed a higher chance for recurrence than those who did not (ADAM-28: Neg. vs. Pos.: 26mon vs. 15mon, P = 0.050; ADAM-10: Neg. vs. Pos.: 41mon vs. 17mon, P = 0.020; AD1 M-17: Neg. vs. Pos.: 39mon vs. 17mon, P = 0.010). (A1, B1, C1) Patients overexpressing ADAM-28 (A1), ADAM-10 (B1), and ADAM-17 (C1) showed a decreased survival duration compared to patients who did not (ADAM-28: Neg. vs. Pos.: 26mon vs. 17mon, P = 0.074; ADAM-10: Neg. vs. Pos.: 50mon vs. 17mon, P = 0.010; AD1 M-17: Neg. vs. Pos.: 42mon vs. 15mon, P = 0.003)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us